Pharmaceuticals News & Press Release Distribution

Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo (CIIE)

SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- At the opening ceremony of the 4th China International Import Expo (CIIE) held inShanghai on November 6, 2021, SYZJ001, a bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech Co., Ltd. and Sanyou Biopharmaceuticals (Shanghai) ...

2021-11-22 21:00 1993

Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo (CIIE)

TenNor Reports Positive Results of TNP-2092 Capsule for the Treatment of Liver Cirrhosis Hyperammonemia

SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy in patients with liver cirrhosis. TNP-2092 Capsule is an investigational new drug produ...

2021-11-22 21:00 1910

Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021

SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-11-22 08:16 4371

Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index

SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-11-22 08:00 4979

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...

2021-11-21 17:09 4451

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...

2021-11-21 17:02 4516

Successful 2020 Tang Prize Award Ceremony Highlights Laureates' Achievements and Influence

TAIPEI, Nov. 20, 2021 /PRNewswire/ -- The 2020 Tang Prize Award Ceremony took place virtually at 2p.m. (GMT+8) onNovember 20. Eight 2020 recipients of the prize from seven countries, including the U.S., the U.K.,Japan, Singapore, Bangladesh, Colombia, and Lebanon, attended this heartwarming event...

2021-11-20 15:00 3621

Successful 2020 Tang Prize Award Ceremony Highlights Laureates' Achievements and Influence

Brii Biosciences Joins Hang Seng Composite Index

DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that Brii Biosciences has been included as a constituent stock of the Hang Seng Composite Index. Dr. Ankang L...

2021-11-19 19:06 4771

Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2021-11-19 19:00 3116

YHLO Revealed Its New Development of CLIA Technology at MEDICA 2021

DUSSELDORF, Germany, Nov. 19, 2021 /PRNewswire/ -- Shenzhen YHLO Biotech Co., Ltd (688575.SSE), an innovative and steadfastly growing company of immunoassay solutions, presented its compact and automated chemiluminescence immunoassay (CLIA) analyzer iFlash 1200 at Medica 2021, a world-renowned tr...

2021-11-19 14:43 2748

111, Inc. Announces Third Quarter 2021 Unaudited Financial Results

SHANGHAI, Nov. 19, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the third quart...

2021-11-19 13:31 3793

ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine

SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional...

2021-11-19 13:14 1877

EQT Infrastructure to acquire Icon Group, Australia's largest integrated cancer care provider

- EQT Infrastructure has agreed to acquire Icon Group from a consortium including Goldman Sachs Asset Management, QIC and Pagoda. Goldman Sachs Asset Management will remain a minority shareholder as part of the transaction - Icon Group is Australia's largest vertically integrated cancer care...

2021-11-19 10:21 4280

Investment Confidence in Icon Group to Drive Next Phase of Global Growth With EQT Infrastructure Investment

BRISBANE, Australia, Nov. 19, 2021 /PRNewswire/ -- Icon Group has today announced it will enter the next phase of global expansion of its transformative integrated cancer care model following the investment of global investment organisation EQT. The investment demonstrates confidence in the stre...

2021-11-19 09:19 3003

Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma

SHANGHAI and Hong Kong, Nov. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-11-19 08:30 4289

Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing

NEW YORK and HONG KONG, Nov. 18, 2021 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, today announced the closing of an oversubscribed Series B financing, which raised more than$91...

2021-11-18 20:00 3637

ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of growth

Dr. Steffen Wagner appointed as new Chief Executive Officer and Andreas Stickler as new Chief Financial Officer LONDON, Nov. 18, 2021 /PRNewswire/ -- ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in ...

2021-11-18 15:45 5629

ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of growth

China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China

SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- China's pharma industry has seen a record improvement in its overall score, growth potential and biologics according to new data. TheChina specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China - which will take pla...

2021-11-18 15:00 1670

China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China

SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- China's pharma industry has seen a record improvement in its overall score, growth potential and biologics according to new data. TheChina specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China - which will take pla...

2021-11-18 15:00 1923

First Subject Dosed in the U.S. Phase I Trial for ASC43F Only Half a Month after IND Approval by the U.S. FDA

SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces dosing of the first subject in the U.S. Phase I trial for ASC43F, a first-in-class, fixed-dose combination (FDC) oral tablet with dual targets of thyroid h...

2021-11-18 08:30 4020